Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | AZD1390 + Tazemetostat |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| AZD1390 | AZD 1390|AZD-1390 | ATM Inhibitor 13 | AZD1390 is a selective inhibitor of ATM that is optimized for blood-brain barrier penetration, thus may preferentially sensitize CNS tumors for radiotherapy (Mol Cancer Ther 2018;17(1 Suppl):Abstract nr A104, PMID: 29938225, PMID: 31299316). | |
| Tazemetostat | Tazverik | EPZ6438|E-7438|EPZ-6438 | EZH2 inhibitor 20 | Tazverik (tazemetostat) binds to and inhibits EZH2, resulting in decreased tri-methylation of H3K27, which potentially leads to inhibition of cell proliferation and tumor growth (PMID: 23620515). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|